Results 91 to 100 of about 479 (110)

Revolutionizing tuberculosis treatment: Breakthroughs, challenges, and hope on the horizon. [PDF]

Acta Pharm Sin B
Kufa M, Finger V, Kovar O, Soukup O, Torruellas C, Roh J, Korabecny J.   +6 more
europepmc   +1 more source

Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trial.

Lancet Infect Dis
Dawson R, Diacon AH, Variava E, Moloantoa T, Brumskine W, Ngwanto T, Zuma-Gwala N, Osman A, Rassool M, Bennet JA, Liu Y, Xu R, Li W, Takuva S, Hafkin J.   +14 more
europepmc   +1 more source

Spectroscopic identification of intermediates and final products of the chiral pool synthesis of sutezolid

Journal of Molecular Structure, 2020
Abstract Sutezolid is a new oxazolidinone derivative currently in clinical trials to determine its safety and efficacy towards highly drug-resistant tuberculosis. The aim of the study was the spectroscopic identification of selected key intermediate products of the chiral pool synthesis of sutezolid: (S1) (4-(2-fluoro-4-nitrophenyl)thiomorpholine ...
Mikołaj Mizera, Kornelia Lewandowska, Katarzyna Michalska   +2 more
exaly   +4 more sources

Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial

Lancet Infectious Diseases, The
Linezolid is a key component globally in first-line therapy for drug-resistant tuberculosis but has considerable toxicity. New and safer alternative oxazolidinones are needed. Sutezolid is one such promising alternative. We aimed to evaluate preliminary efficacy and safety of sutezolid and to identify an optimal dose.PanACEA-SUDOCU-01 was a prospective,
Gibson Kibiki, Kim Narunsky, Hadija Semvua   +2 more
exaly   +8 more sources

Synergistic activity of fosfomycin combined with old and new oxazolidinones (linezolid, contezolid, delpazolid, and sutezolid) against bloodstream isolates of vancomycin-resistant Enterococcus faecium

European Journal of Clinical Microbiology and Infectious Diseases
Current treatment options for infections caused by vancomycin-resistant (VR) Enterococcus faecium remain limited and often suboptimal. This study investigates the in vitro activity of combination therapies involving fosfomycin and oxazolidinones (linezolid, contezolid, delpazolid, and sutezolid) against five vanA and five vanB E.
Cristina Lagatolla, Stefano Di Bella, Verena Zerbato   +2 more
exaly   +5 more sources

Pharmacokinetics of tedizolid, sutezolid, and sutezolid-M1 in non-human primates

European Journal of Pharmaceutical Sciences, 2020
Non-human primates (NHP) are thought to be a good preclinical animal model for tuberculosis because they develop disease characteristics that are similar to humans. The objective of the current study was to determine if NHPs can also be used to reliably predict the exposure of tedizolid, sutezolid, and its biologically active metabolite sutezolid-M1 in
JoAnne Flynn, Charles A Peloquin, Veronique Dartois   +2 more
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

The synthesis of sutezolid and eperezolid using proline catalyzed α-aminoxylation of an aldehyde

Journal of Chemical Sciences, 2022
Varadaraj Bhat, Gautham Shenoy
exaly   +2 more sources

Characterization of degradation products and process-related impurity of sutezolid by liquid chromatography/electrospray ionization tandem mass spectrometry

Journal of Pharmaceutical and Biomedical Analysis, 2019
Sutezolid was a new oxazolidinone compound used for the treatment of M. tuberculosis. This study describes the separation, characterization and in silico toxicity prediction of three degradation products and one process-related impurity of sutezolid.
Chen Ma
exaly   +3 more sources

Enantioselective recognition of sutezolid by cyclodextrin modified non-aqueous capillary electrophoresis and explanation of complex formation by means of infrared spectroscopy, NMR and molecular modelling

Journal of Pharmaceutical and Biomedical Analysis, 2019
A method for the enantioseparation of sutezolid, the next analogue after linezolid and tedizolid, belonging to the truly new class of antibacterial agents, the oxazolidinones, was developed based on non-aqueous capillary electrophoresis (NACE), using a single isomer of cyclodextrins as a chiral pseudophase.
Elzbieta Bednarek, Katarzyna Michalska, Judyta Cielecka-Piontek   +2 more
exaly   +4 more sources